Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 13/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.38 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253536 | 1.00 | DGAT1 (0.39) | DGAT1NPC1HCAR3SOAT2FAAH | |
| SCHEMBL1399591 | 0.89 | ALDH1A1 (0.39) | DGAT1NPC1 | |
| SCHEMBL12809357 | 0.89 | ALDH1A1 (0.39) | DGAT1NPC1 | |
| SCHEMBL1399620 | 0.81 | NPC1 (0.37) | DGAT1NPC1HCAR3 | |
| SCHEMBL1399622 | 0.81 | NPC1 (0.37) | DGAT1NPC1HCAR3 | |
| SCHEMBL1399743 | 0.79 | ALDH1A1 (0.39) | NPC1 | |
| SCHEMBL1399740 | 0.79 | ALDH1A1 (0.39) | NPC1 | |
| SCHEMBL1399762 | 0.78 | DGAT1 (0.40) | DGAT1NPC1 | |
| SCHEMBL1399760 | 0.78 | DGAT1 (0.40) | DGAT1NPC1 | |
| SCHEMBL1399612 | 0.77 | MAPT (0.37) | NPC1HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | DGAT1, ACAT1, DGAT2 | DGAT1 1/4885NPC1 615/4885HCAR3 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.